1. Ua kūʻai ʻia aku nā tausani o nā lāʻau lapaʻau maʻamau o COVID-19?nānā i waho!
I kēia mau lā, ua kūʻai ʻia kahi kumuhana e pili ana i "COVID-19 Indian generic drugs no nā kaukani yuan i loko o kahi pahu" i ʻike ʻia ma ka papa inoa hulina microblog kaulana.Ua kūʻai ʻia kekahi mau lāʻau lapaʻau ma ka ʻaoʻao o China News Network, a ua kūʻai ʻia ke kumukūʻai, no laila pono e hoʻopaʻa ʻia i hoʻokahi pule ma mua.Hoʻomanaʻo nā kauka ʻaʻole pono e kūʻai ʻia nā lāʻau lapaʻau ma o nā ala ʻike ʻole.Eia kekahi, ʻaʻole pono nā hui koʻikoʻi e hoʻohana i ka lāʻau lapaʻau waha COVID-19.
ʻO ke kumu kūʻai mua o kahi pahu lāʻau he 2300 yuan, a ʻo ke kumukūʻai kūʻai ma India he 1600 yuan.
"I kēia manawa ua hoʻopaʻa ʻia nā kauoha."Ua haʻi aku kekahi mau mea kūʻai lāʻau lapaʻau India iā chinanews.com ua kūʻai ʻia kā lākou Pfizer COVID-19 waha Paxlovid generic lāʻau lapaʻau i kēia manawa.Inā pono, hiki iā lākou ke uku mua i ka waihona, a hiki ke hoʻouna ʻia nā waiwai i loko o hoʻokahi pule i ka wā mua, a i ʻole ka mahina aʻe ma ka lohi.
Inā hoʻokomo ʻia nā huaʻōlelo "COVID-19 India", "COVID-19 generic drugs" a pēlā aku ma ka platform e-commerce, hiki i nā mea kūʻai ke loaʻa koke i ka ʻike o kēia mau mea kūʻai aku, akā pono lākou e hoʻohui i nā hoa WeChat, a a laila e hoʻomaopopo i ka ʻike kikoʻī a me nā koi kūʻai.
ʻO nā lāʻau lapaʻau maʻamau ʻo Paxlovid i kūʻai ʻia e kēia mau mea hana ʻo Primovir i loko o ka ʻeke ʻōmaʻomaʻo a me Paxista i ka ʻeke polū.ʻO ka mea mua i hana ʻia e Astrica, kahi hui India, aʻo ka mea hope i hana ʻia e Azista, kahi lālā o ka ʻoihana lāʻau lapaʻau India Hetero.I kēia manawa, ua ho'ōki ka Primovir me ka ʻeke ʻōmaʻomaʻo i ka hana ʻana, a ʻo Paxista wale nō me ka ʻeke polū ke kūʻai aku nei.
Ua hōʻike mai kekahi ʻelele he 1600 yuan ke kumu kūʻai o ka leka uila no ka pahu, a ʻo ke kumu kūʻai o ka leka uila ma nā ʻāina ʻē he 1200 yuan no ka pahu, ʻoi aku ka liʻiliʻi o 400 yuan.ʻO ke kumukūʻai kūʻai o Paxlovid ma Kina he 2300 yuan no ka pahu.
He paʻakikī kēia mau lāʻau lapaʻau maʻamau i ke kūʻai ʻana i kēia manawa.Wahi a ka mea kūʻai aku i luna, ʻae ʻia nā hoʻopaʻa ʻana, a hiki mai ka leka uila India ma Kina ma kahi o 15-20 mau lā.Ua ʻōlelo pū ʻo ia e hiki i kēlā me kēia kanaka ke kūʻai wale i 2 pahu.
Hoʻomanaʻo nā kauka: He paʻakikī ke haʻi i ka ʻoiaʻiʻo a me ka hoʻopunipuni.E noho makaala
I ka ʻoiaʻiʻo, ua hoʻohana lōʻihi ʻia ʻo Paxlovid i ka mālama ʻana i ka maʻi COVID-19 ma Kina, akā hoʻohana nui ʻia ia i kekahi mau halemai i koho ʻia a koi ʻia ka ʻae ʻana o nā ʻōlelo a nā kauka.ʻAʻole loaʻa ka lāʻau lapaʻau i nā halemai a pau.
He mea pono e hoʻomaopopo i kekahi mau lāʻau lapaʻau maʻamau i kūʻai ʻia ma ke kumu komisina hiki ke kūʻai ʻia me ka ʻole o ka hāʻawi ʻana i kahi ʻōlelo kuhikuhi.Ma kēiaʻano, hoʻomanaʻo nā kaukaʻoihana i nā mea a pau e makaʻala.
"Ma ke ʻano he kauka lapaʻau, ʻaʻole mākou e aʻo e kūʻai i nā mea hoʻohālike haole, no ka mea paʻakikī ke haʻi i ka ʻoiaʻiʻo mai ka hoʻopunipuni."Ua haʻi aku ʻo Zhang Jiming, ka hope luna o ka National Infectious Diseases Medical Center a me ke kauka nui, ke kaukaʻi a me ka luna kauka kauka o Huashan Hospital i pili i ke Kulanui ʻo Fudan.com ua kūʻai pilikino kekahi o nā maʻi āna i nīnauele ai a i ʻole ko lākou ʻohana i nā mea hoʻohālike, a hopohopo lākou e kūʻai ana lākou i nā lāʻau lapaʻau hoʻopunipuni.Ua ʻōlelo ʻo ia he mea paʻakikī ke hōʻoia i ka maikaʻi o nā lāʻau lapaʻau mai ke kumu a me nā kūlana mālama o nā lāʻau i ke kūʻai ʻana i nā lāʻau lapaʻau ma waho.
Ua hoʻolaha ʻo Zhang Jiming e hoʻohana nui ʻia ka lāʻau lapaʻau waha COVID-19 no nā hui koʻikoʻi e pale aku i nā maʻi koʻikoʻi, a hiki ke hoʻohana wale ʻia ke hoʻohana mua ʻia.ʻAʻole pono nā hui pilikia ʻole e wikiwiki e kūʻai, a hiki i ka hoʻomāinoino ke hoʻoulu i ke kūʻē ʻana i ka lāʻau.ʻAʻole pono ia i ka maʻi maʻi, no ka mea, ʻo ka hapa nui o nā maʻi he asymptomatic a ʻoluʻolu paha, a ʻo ke ʻano o ka maʻi i kaupalena ʻia.
Ua haʻi ʻo ia iā chinanews.com e pili ana i ke kūlana ma Shanghai, nā halemai nui, nā halemai i koho ʻia ʻo COVID-19 a me nā keʻena lapaʻau ʻē aʻe i loaʻa i kahi nui o nā lāʻau anti COVID-19, i hoʻohana ʻia e nā pūʻulu koʻikoʻi e kū nei i nā hōʻailona a i hoʻopaʻa ʻia me COVID-19, i mea e pale ai i ka maʻi koʻikoʻi a hoʻemi i ka nui o ka make.
Eia kekahi, e like me ka hōʻike ʻana o ka pāpā, hoʻomanaʻo nā limahana loio i ka India COVID-19 generic lāʻau i kūʻai ʻia ma ka pūnaewele ʻaʻole i ʻae ʻia ma Kina.Ma lalo o ke Kānāwai Drug Administration o ka People's Republic of China i kēia manawa, ʻoiai ʻo nā lāʻau lapaʻau i helu ʻia ma waho akā ʻaʻole i ʻae ʻia ma Kina ʻaʻole i ʻike hou ʻia he mau lāʻau lapaʻau hoʻopunipuni, e hoʻopaʻi mau ana nā mea hana no ka lawe ʻana mai i nā lāʻau lapaʻau.
2. Ua hala ʻo Xinlitai!E paʻa ana i ʻelua mau ʻano 1 biliona, 11 mau ʻano o ka papa 1 mau lāʻau hou.
I kēia mau lā, ua holomua hou ʻo Xinlitai R&D pipeline.Ua hoʻohana ʻia nā papa SAL0133 hou o ka papa 1 no ka hoʻohana lāʻau lapaʻau.Ua loaʻa nā hualoaʻa helu helu mua mai ka Phase Ib hoʻokolohua hoʻokolohua o PCSK9 monoclonal antibody.Mai ka makahiki 2022, ua noi ʻo Xinlitai no IND/NDA no nā lāʻau lapaʻau hou 7, a ua hoʻolaha mau ʻia ka noiʻi a me ka hoʻomohala ʻana.I kēia manawa, loaʻa iā Xinlitai ʻelua mau ʻano like ʻole 1 biliona, 22 o ia mau mea i loiloi ʻia (8 ka mea mua);Aia ma lalo o ka noiʻi ʻana he 21 mau lāʻau lapaʻau, ʻo 6 o lākou i ke kahua lapaʻau o NDA a i ʻole Phase III, a ua komo ka pipeline hou i ka manawa kālā.
ʻIke ʻia ka lāʻau lapaʻau waha COVID-19 ākea ākea!Komo ʻo Xinlitai i ka Kaapuni COVID-19
Ma Kekemapa 20, ua hoʻolaha ʻo Xinlitai i ka noi ʻana o SAL0133, kahi lāʻau liʻiliʻi liʻiliʻi i hoʻomohala kūʻokoʻa e ka hui, ua ʻae ʻia e ka State Food and Drug Administration.ʻO SAL0133 kahi mea hoʻopaneʻe ikaika, ākea ākea anti novel coronavirus 3CL protease (3CLpro) i hoʻomohala kūʻokoʻa a hoʻomohala ʻia e ka hui me nā kuleana waiwai naʻauao kūʻokoʻa.I kēia manawa, ʻo ka hōʻailona lapaʻau e hoʻomohala ʻia ʻo ia ka mālama ʻana i ka maʻi maʻi maʻamau o ka maʻi maʻamau o ka maʻi maʻi coronavirus (COVID-19).
He kuleana koʻikoʻi ka 3CLpro i ka hoʻopili hou ʻana o RNA o ka coronavirus novel, ka mea nui ma ka pae hoʻopiʻi mua ma hope o ke komo ʻana o ka maʻi i loko o ka hale hoʻokipa, ke kāohi nei i ka hana o ka 3CLpro protease, hiki ke hoʻopaʻa pono i ka hoʻopiʻi hou ʻana a hoʻokō i ke kuleana o ka anti novel coronavirus.
Loaʻa i ka SAL0133 kahi hana akaka o ka hana, a he hopena ikaika, ākea ākea anti COVID-19.Manaʻo ʻia ʻaʻole pono ia e hui pū me ka ritonavir inhibitor CYP3A4, a haʻahaʻa ka pilikia o ka pilina o ka lāʻau;Manaʻo ʻia e hoʻokō i ka hoʻohana lāʻau lapaʻau hoʻokahi i hoʻokahi lā a hoʻomaikaʻi i ka mālama ʻana i ka lāʻau maʻi.Inā hiki ke hoʻomohala maikaʻi ʻia a ʻae ʻia no ke kūʻai aku ʻana, e hāʻawi ia i nā mea maʻi i nā koho lāʻau hou e hoʻokō i nā pono lapaʻau pono ʻole.
ʻO ka noiʻi ʻana a me ka hoʻomohala ʻana o ka 3CL target anti COVID-19 waha liʻiliʻi liʻiliʻi lāʻau lāʻau i huki nui ʻia.I kēia manawa, ʻo Pfizer's Paxlovid wale nō i ʻae ʻia no ke kūʻai aku ma ka honua.ʻOi aku ma mua o 10 mau ʻoihana lāʻau lapaʻau kūloko a me nā keʻena noiʻi ʻepekema e hana nei i ka noiʻi a me ka hoʻomohala ʻana i nā lāʻau lapaʻau 3CL target anti COVID-19, me FB2001 o Frontier Biology, VV993 o Junshi Biology/Wangshan Wangshui, SIM0417 o Pioneer Pharmaceutical, RAY1216 papa o Zhongsheng GST-HG171 o Guangshengtang, etc.
Me 2 mau ʻano nui 1 biliona ma ka lima, 7 mau lāʻau hou i kēia makahiki e hoʻokipa i ka holomua hou
Ma ka hopena o 2022, ma ke ʻano he ʻelele maʻamau o ka hoʻololi R&D i ka ʻoihana lāʻau lapaʻau, ua loaʻa ʻo Xinlitai i kāna ala hoʻomohala ponoʻī ma lalo o ke kaomi a me ka hoʻoponopono.
I nā hapaha mua ʻekolu o 2022, ʻo ka loaʻa kālā o ka ʻoihana he 2.548 biliona yuan, me ka ulu ʻana o ka makahiki-ma-makahiki o 16.5%, a ʻo kāna waiwai kālā he 539 miliona yuan, me ka ulu ʻana o ka makahiki-ma-makahiki o 37.64%.Hoʻokumu ka hana maikaʻi i kumu paʻa no ka hoʻomohala ʻana ma hope.Manaʻo ka hui ma 2022, e loaʻa iā Taijia (clopidogrel bisulfate tablets) ma kahi o 1 billion yuan, a ʻo Sinritan (alisartan tablets) e loaʻa iā 900 miliona yuan a 1 billion yuan.He 22 mau ʻano like ʻole ka hui, ʻo 8 ka mea mua ma Kina.
I ka makahiki 2019, ua nalowale ke ʻano nui o Xinlitai, Taijia, i kāna koho ʻana i ke kūʻai kūʻai kikowaena 4 + 7, nāna i koi iā Xinlitai e hana i nā loli.Ma ka hōʻike makahiki 2019, ua hoʻolaha ʻo Xinlitai "e hoʻolālā maikaʻi ʻia ka pipeline noiʻi, a e hoʻopau ʻia ka anti-tumor biological analog a me nā papahana antibiotic i kekahi mau pae lapaʻau".Ma 2020, i mea e hoʻonui ai i ka pipeline ma lalo o ka noiʻi a me ka nānā ʻana i ka R&D a me ka hoʻolaha ʻana i nā huahana hou, ua hoʻololi ʻo Xinlitai i nā kuleana kūpono a me nā pono o dapoxetine hydrochloride, erlotinib hydrochloride, rivasaban a me nā papahana ʻē aʻe, a loaʻa iā ia kahi uku hoʻololi.
Ma hope o kekahi mau hoʻololi ʻana, i kēia manawa, ʻo ka pipeline lāʻau lapaʻau maʻamau o Xinritai wale nō ka papa 4 marketing noi no ka hoʻohālikelike ʻana i nā papa sodium Sakubatrovalsartan ma lalo o ka loiloi, a me ka noi hoʻohui no ka loiloi kūlike o ka sodium cefuroxime no ka injection a me ka sodium cefotaxime no ka injection ma lalo o ka loiloi.He mea kūpono e haʻi ʻia mai Iulai 2019, ʻaʻole i noi ʻo Xinlitai i nā lāʻau lapaʻau hou no nā makahiki he 3, a ʻoi aku ka nui o ka hana hou a me ka noiʻi.
Mai ka makahiki 2022, ua holomua ʻo Xinlitai i ka noiʻi a me ka hoʻomohala ʻana i nā lāʻau lapaʻau hou.Ma Ianuali 4, 2022, ua lawe ʻia ka papa inoa o ka papa inoa o ka CINRITAI's HIF-PHI inhibitor Enasitar papa e CDE;Ma hope mai, ua hāʻawi ka Hui i nā palapala noi no nā lāʻau lapaʻau hou ʻelima o ka Papa 1, ʻo ia hoʻi, recombinant human neuromodulin-1 anti HER3 antibody fusion protein injection, SAL0112 papa, SAL008 injection, SAL0119 papa a me SAL0133 papa;Ma ka lā 3 Nowemapa, ua hoʻouna ka papa 2.3 hou o ka lāʻau alisartan a me nā papa amlodipine o SINRITAI i kahi noi no ka papa inoa, i manaʻo ʻia e hana i ka synergy hoʻolālā me ka papa inoa 1.1 antihypertensive lāʻau SINRITAI.
ʻO JinDun Medicalloaʻa i ka hui noiʻi ʻepekema lōʻihi a me ka grafting ʻenehana me nā kulanui Kina.Me nā waiwai lapaʻau waiwai o Jiangsu, loaʻa iā ia nā pilina kālepa lōʻihi me India, Asia Hema, South Korea, Iapana a me nā mākeke ʻē aʻe.Hāʻawi pū ia i nā lawelawe mākeke a me ke kūʻai aku i ke kaʻina holoʻokoʻa mai waena a hiki i ka huahana huahana API.E hoʻohana i nā kumuwaiwai i hōʻiliʻili ʻia o Yangshi Chemical i loko o ka kemika fluorine e hoʻolako i nā lawelawe hana hana kemika kūikawā no nā hoa.Hāʻawi i nā lawelawe noiʻi kaʻina hana a me ka haumia i nā mea kūʻai aku.
Ke koi nei ʻo JinDun Medical i ka hoʻokumu ʻana i kahi hui me nā moeʻuhane, hana i nā huahana me ka hanohano, meticulous, rigorous, a hele i nā mea a pau e lilo i hoa hilinaʻi a me ka hoaaloha o nā mea kūʻai aku! ʻoihanahana lāʻau lapaʻau maʻamau(CMO) a me nā mea lawelawe R&D lāʻau lapaʻau maʻamau a me ka hana (CDMO).E hele pū ʻo Jindun iā ʻoe e hoʻolilo iā COVID-19.
Ka manawa hoʻouna: Jan-28-2023